Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma

International Journal of Oncology

Volumn 28, Issue 3, 2006, Pages 767-773

  Wong, Michelle L Y ^a   Tao, Qian ^a,c,d   Fu, L I ^c   Wong, Kai Yau ^a   Qiu, Guo Hua ^c   Law, Fian B F ^a   Tin, Pui Chi ^a   Cheung, Wai Ling ^a   Lee, Ping Yin ^b   Tang, Johnny Cheuk On ^a,e,f   Tsao, George S W ^b   Lam, King Yin ^b   Law, Simon ^b   Wong, John ^b   Srivastava, Gopesh ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c Johns Hopkins Singapore   (Singapore)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^f GRIFFITH UNIVERSITY   (Australia)

Author keywords

3p21; Methylation; Oesophageal carcinoma; RASSF1A; Tumor suppressor gene

Indexed keywords

RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER STAGING; CHINA; CHROMOSOME 3; COMPARATIVE STUDY; DNA METHYLATION; ESOPHAGUS TUMOR; GENETICS; HUMAN; INCIDENCE; JAPAN; PATHOLOGY; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHINA; CHROMOSOMES, HUMAN, PAIR 3; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; INCIDENCE; JAPAN; NEOPLASM STAGING; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 33645237758     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.3.767     Document Type: Article

References (43)

1. Ferlay J, Bray F, Pisani P and Parkin DM: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. Version 2.0. IARC Press, Lyon, 2004.
2. Lam KY: Molecular biology of oesophageal squamous cell carcinoma. Crit Rev Oncol Hematol 33: 71-90, 2000.
3. Tang JCO, Lam KY, Law S, Wong J and Srivastava G: Detection of genetic alterations in oesophageal squamous cell carcinomas and adjacent normal epithelia by comparative DNA fingerprinting using inter-simple sequence repeat PCR. Clin Cancer Res 7: 1539-1545, 2001.
4. Hu YC, Lam KY, Law S, Wong J and Srivastava G: Identification of differentially expressed genes in oesophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res 7: 2213-2221, 2001.
5. Hu YC, Lam KY, Law S, Wong J and Srivastava G: Profiling of differentially expressed cancer-related genes in oesophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumour differentiation in ESCC. Clin Cancer Res 7: 3519-3525, 2001. (Pubitemid 33069989)
6. Kan T, Shimada Y, Sato F, Maeda M, Kawabe A, Kaganoi J, Itami A, Yamasaki S and Imamura M: Gene expression profiling in human oesophageal cancers using cDNA microarray. Biochem Biophys Res Commun 286: 792-801, 2001. (Pubitemid 32912957)
7. Zhou J, Zhao LQ, Xiong MM, Wang XQ, Yang GR, Qiu ZL, Wu M and Liu ZH: Gene expression profiles at different stages of human oesophageal squamous cell carcinoma. World J Gastroenterol 9: 9-15, 2003. (Pubitemid 36131269)
8. Su H, Hu N, Shih J, Hu Y, Wang QH, Chuang EY, Roth MJ, Wang C, Goldstein AM, Ding T, Dawsey SM, Giffen C, Emmert-Buck MR and Taylor PR: Gene expression analysis of oesophageal squamous cell carcinoma reveals consistent molecular profiles related to a family history of upper gastrointestinal cancer. Cancer Res 63: 3872-3386, 2003. (Pubitemid 36917896)
9. Baylin SB and Herman JG: DNA hypermethylation in tumourigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000.
10. Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M, Sakata K, Sato N, Saito K and Satodate R: Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage oesophageal squamous cell carcinoma. Cancer Res 56: 3875-3878, 1996.
11. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M and Ishizaki K: Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in oesophageal squamous cell carcinomas. Cancer Res 58: 3429-3434, 1998.
12. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD and Yang CS: Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human oesophageal squamous cell carcinoma. Clin Cancer Res 5: 2704-2713, 1999.
13. Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, Wang LD and Yang CS: DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human oesophageal squamous cell carcinomas. Carcinogenesis 22: 1615-1623, 2001.
14. Si HX, Tsao SW, Lam KY, Srivastava G, Liu Y, Wong YC, Shen ZY and Cheung AL: E-cadherin expression is commonly downregulated by CpG island hypermethylation in oesophageal carcinoma cells. Cancer Lett 173: 71-78, 2001.
15. Zhang L, Lu WF, Miao XP, Xing DY, Tan W and Lin DX: Inactivation of DNA repair gene O-6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in oesophageal squamous cell carcinoma. Carcinogenesis 24: 1039-1044, 2003.
16. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M and Croce CM: Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumour suppressor genes on chromosome 3p in oesophageal squamous cell carcinoma. Cancer Res 63: 3724-3728, 2003.
17. Wang Y, Fang MZ, Liao J, Yang GY, Nie Y, Song Y, So C, Xu X, Wang LD and Yang CS: Hypermethylation-associated inactivation of retinoic acid receptor beta in human oesophageal squamous cell carcinoma. Clin Cancer Res 9: 5257-5263, 2003.
18. Yue CM, Deng DJ, Bi MX, Guo LP and Lu SH: Expression of ECRG4, a novel oesophageal cancer-related gene, downregulated by CpG island hypermethylation in human oesophageal squamous cell carcinoma. World J Gastroenterol 9: 1174-1178, 2003.
19. Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, Murakami Y and Imamura M: Involvement of TSLC1 in progression of oesophageal squamous cell carcinoma. Cancer Res 63: 6320-6326, 2003.
20. Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, Weichselbaum R, Kuo MJ, Maher ER and Latif F: Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 38: 1585-1592, 2002.
21. Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumour suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumour Suppressor Gene Consortium. Cancer Res 60: 6116-6133, 2000.
22. Dammann R, LC, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000.
23. Hesson L, Dallol A, Minna JD, Maher ER and Latif F: NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22: 947-954, 2003.
24. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001.
25. Dammann R, Takahashi T and Pfeifer GP: The CpG island of the novel tumour suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 20: 3563-3567, 2001.
26. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G and Zabarovsky ER: The candidate tumour suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumourigenesis. Proc Natl Acad Sci USA 98: 7504-7509, 2001.
27. Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG and Chi SG: Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61: 6688-6692, 2001.
28. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP and Dammann R: Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62: 3698-3701, 2002.
29. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ and Huang DP: Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8: 131-137, 2002. (Pubitemid 34101468)
30. Qiu GH, Tan LKS, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW and Tao Q: The candidate tumour suppressor gene BLU, located at the commonly deleted region 3p21, is an E2F-regulated, stress-responsive gene, and inactivated by epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 23: 4793-4806, 2004.
31. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP and Hoon DS: Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63: 1639-1643, 2003.
32. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B and Dammann R: Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 22: 1866-1871, 2003.
33. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Linehan WM and Lerman MI: The RASSF1A tumour suppressor gene is inactivated in prostate tumours and suppresses growth of prostate carcinoma cells. Cancer Res 62: 3498-3502, 2002.
34. Liu L, Yoon JH, Dammann R and Pfeifer GP: Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 21: 6835-6840, 2002.
35. Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Heys D, Agathanggelou A, Latif F, Grundy RG, Mann JR, Starczynski J, Crocker J, Parkes SE, Ambinder RF, Young LS and Tao Q: Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in Hodgkin's lymphoma. Oncogene 23: 1327-1332, 2004.
36. Kwong D, Lam KY, Guan X, Law S, Wong J and Sham J: Chromosomal aberrations in oesophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. Hum Pathol 35: 309-316, 2004.
37. Ko JM, Wong CP, Tang CM, Lau KW and Lung ML: Frequent loss of heterozygosity on multiple chromosomes in Chinese oesophageal squamous cell carcinomas. Cancer Lett 170: 131-138, 2001.
38. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M and Croce CM: Promoter hypermethylation of RASSF1A in oesophageal squamous cell carcinoma. Clin Cancer Res 9: 1441-1445, 2003.
39. Hu Y, Lam KY, Wan TS, Fang W, Ma ES, Chan LC and Srivastava G: Establishment and characterization of HKESC-1, a new cancer cell line from human oesophageal squamous cell carcinoma. Cancer Genet Cytogenet 118: 112-120, 2000.
40. Tang JC, Wan TS, Wong N, Pang E, Lam KY, Law SY, Chow LM, Ma ES, Chan LC, Wong J and Srivastava G: Establishment and characterization of a new xenograft-derived human oesophageal squamous cell carcinoma cell line SLMT-1 of Chinese origin. Cancer Genet Cytogenet 124: 36-41, 2001. (Pubitemid 32101470)
41. Hu YC, Lam KY, Law SY, Wan TS, Ma ES, Kwong YL, Chan LC, Wong J and Srivastava G: Establishment, characterization, karyotyping, and comparative genomic hybridization analysis of HKESC-2 and HKESC-3: two newly established human oesophageal squamous cell carcinoma cell lines. Cancer Genet Cytogenet 135: 120-127, 2002. (Pubitemid 34786763)
42. Deng W, Tsao SW, Guan XY, Lucas JN, Si HX, Leung CS, Mak P, Wang LD and Cheung AL: Distinct profiles of critically short telomeres are a key determinant of different chromosome aberrations in immortalized human cells: whole-genome evidence from multiple cell lines. Oncogene 23: 9090-9101, 2004. (Pubitemid 40013076)
43. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.